{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T09:45:18Z","timestamp":1784713518186,"version":"3.55.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T00:00:00Z","timestamp":1666656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T00:00:00Z","timestamp":1666656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Research Grants Council of the Hong Kong SAR Government","award":["T11-712\/19-"],"award-info":[{"award-number":["T11-712\/19-"]}]},{"name":"Research Grants Council Senior Research Fellowship","award":["HKU SRFS2021-7S03"],"award-info":[{"award-number":["HKU SRFS2021-7S03"]}]},{"DOI":"10.13039\/100000060","name":"The National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","award":["75N93021C00016"],"award-info":[{"award-number":["75N93021C00016"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Dose fractionation of a coronavirus disease 2019 (COVID-19) vaccine could effectively accelerate global vaccine coverage, while supporting evidence of efficacy, immunogenicity, and safety are unavailable, especially with emerging variants.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We systematically reviewed clinical trials that reported dose-finding results and estimated the dose-response relationship of neutralizing antibodies (nAbs) of COVID-19 vaccines using a generalized additive model. We predicted the vaccine efficacy against both ancestral and variants, using previously reported correlates of protection and cross-reactivity. We also reviewed and compared seroconversion to nAbs, T cell responses, and safety profiles between fractional and standard dose groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We found that dose fractionation of mRNA and protein subunit vaccines could induce SARS-CoV-2-specific nAbs and T cells that confer a reasonable level of protection (i.e., vaccine efficacy &gt; 50%) against ancestral strains and variants up to Omicron. Safety profiles of fractional doses were non-inferior to the standard dose.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Dose fractionation of mRNA and protein subunit vaccines may be safe and effective, which would also vary depending on the characteristics of emerging variants and updated vaccine formulations.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12916-022-02600-0","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T13:02:47Z","timestamp":1666702967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Immunogenicity, efficacy, and safety of SARS-CoV-2 vaccine dose fractionation: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0811-8332","authenticated-orcid":false,"given":"Bingyi","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huizhi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy H.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim K.","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Cowling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,25]]},"reference":[{"issue":"3","key":"2600_CR1","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1473-3099(21)00566-1","volume":"22","author":"EJ Haas","year":"2022","unstructured":"Haas EJ, McLaughlin JM, Khan F, Angulo FJ, Anis E, Lipsitch M, et al. Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study. Lancet Infect Dis. 2022;22(3):357\u201366.","journal-title":"Lancet Infect Dis"},{"key":"2600_CR2","doi-asserted-by":"publisher","unstructured":"Mesl\u00e9 MM, Brown J, Mook P, Hagan J, Pastore R, Bundle N, Spiteri G, et al. Estimated number of deaths directly averted in people 60 years and older as a result of COVID-19 vaccination in the WHO European Region, December 2020 to November 2021. Euro Surveill. 2021;26(47):2101021. https:\/\/doi.org\/10.2807\/1560-7917.ES.2021.26.47.2101021. Erratum in: Euro Surveill. 2022 May;27(21): Erratum in: Euro Surveill. 2022 Jun;27(24).","DOI":"10.2807\/1560-7917.ES.2021.26.47.2101021"},{"issue":"7","key":"2600_CR3","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41562-021-01122-8","volume":"5","author":"E Mathieu","year":"2021","unstructured":"Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, et al. A global database of COVID-19 vaccinations. Nat Hum Behav. 2021;5(7):947\u201353.","journal-title":"Nat Hum Behav"},{"issue":"8","key":"2600_CR4","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/s41591-021-01440-4","volume":"27","author":"BJ Cowling","year":"2021","unstructured":"Cowling BJ, Lim WW, Cobey S. Fractionation of COVID-19 vaccine doses could extend limited supplies and reduce mortality. Nat Med. 2021;27(8):1321\u20133.","journal-title":"Nat Med"},{"key":"2600_CR5","volume-title":"Fractional dose yellow fever vaccine as a dose-sparing option for outbreak response","author":"World Health Organization","year":"2016","unstructured":"World Health Organization: Fractional dose yellow fever vaccine as a dose-sparing option for outbreak response; 2016."},{"issue":"7898","key":"2600_CR6","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41586-022-04399-5","volume":"602","author":"JM Carreno","year":"2022","unstructured":"Carreno JM, Alshammary H, Tcheou J, Singh G, Raskin AJ, Kawabata H, et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature. 2022;602(7898):682\u20138.","journal-title":"Nature"},{"issue":"16","key":"2600_CR7","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","volume":"386","author":"N Andrews","year":"2022","unstructured":"Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022;386(16):1532\u201346.","journal-title":"N Engl J Med"},{"issue":"3","key":"2600_CR8","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41591-022-01704-7","volume":"28","author":"SMS Cheng","year":"2022","unstructured":"Cheng SMS, Mok CKP, Leung YWY, Ng SS, Chan KCK, Ko FW, et al. Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination. Nat Med. 2022;28(3):486\u20139.","journal-title":"Nat Med"},{"issue":"11","key":"2600_CR9","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1038\/s41591-021-01534-z","volume":"27","author":"A Wilder-Smith","year":"2021","unstructured":"Wilder-Smith A, Desai S, Cravioto A, Nohynek H, Hombach J. Caution before fractionating COVID-19 vaccines. Nat Med. 2021;27(11):1856\u20137.","journal-title":"Nat Med"},{"key":"2600_CR10","unstructured":"Interim\u2009 statement on dose-sparing strategies for COVID-19 vaccines (fractionated vaccine doses).\u00a0https:\/\/www.who.int\/news\/item\/10-08-2021-interim-statement-on-dose-sparing-strategies-for-covid-19-vaccines-(fractionated-vaccine-doses). Accessed\u00a01 June 2022."},{"key":"2600_CR11","unstructured":"Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC. https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/covid-19-vaccines-us.html#considerations-covid19-vax-booster. Accessed\u00a01 June 2022."},{"issue":"7","key":"2600_CR12","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205\u201311.","journal-title":"Nat Med"},{"issue":"1","key":"2600_CR13","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1016\/S2666-5247(21)00267-6","volume":"3","author":"D Cromer","year":"2022","unstructured":"Cromer D, Steain M, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe. 2022;3(1):e52\u201361.","journal-title":"Lancet Microbe"},{"issue":"2","key":"2600_CR14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1056\/NEJMc2104974","volume":"385","author":"LJ Abu-Raddad","year":"2021","unstructured":"Abu-Raddad LJ, Chemaitelly H, Butt AA. National Study Group for C-V: effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med. 2021;385(2):187\u20139.","journal-title":"N Engl J Med"},{"issue":"25","key":"2600_CR15","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","volume":"383","author":"EJ Anderson","year":"2020","unstructured":"Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020;383(25):2427\u201338.","journal-title":"N Engl J Med"},{"issue":"10","key":"2600_CR16","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/S1473-3099(21)00200-0","volume":"21","author":"KJ Chappell","year":"2021","unstructured":"Chappell KJ, Mordant FL, Li Z, Wijesundara DK, Ellenberg P, Lackenby JA, et al. Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Infect Dis. 2021;21(10):1383\u201394.","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"2600_CR17","doi-asserted-by":"publisher","first-page":"e3949","DOI":"10.1093\/cid\/ciaa1703","volume":"73","author":"Y Che","year":"2021","unstructured":"Che Y, Liu X, Pu Y, Zhou M, Zhao Z, Jiang R, et al. Randomized, double-blinded, placebo-controlled phase 2 trial of an inactivated severe acute respiratory syndrome Coronavirus 2 vaccine in healthy adults. Clin Infect Dis. 2021;73(11):e3949\u201355.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"2600_CR18","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1038\/s41591-021-01446-y","volume":"27","author":"H Chemaitelly","year":"2021","unstructured":"Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, Tang P, Hasan MR, et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med. 2021;27(9):1614\u201321.","journal-title":"Nat Med"},{"issue":"20","key":"2600_CR19","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1016\/j.vaccine.2021.02.007","volume":"39","author":"L Chu","year":"2021","unstructured":"Chu L, McPhee R, Huang W, Bennett H, Pajon R, Nestorova B, et al. m RNASG: a preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine. 2021;39(20):2791\u20139.","journal-title":"Vaccine"},{"issue":"5","key":"2600_CR20","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJMc2119270","volume":"386","author":"S Collie","year":"2022","unstructured":"Collie S, Champion J, Moultrie H, Bekker LG, Gray G. Effectiveness of BNT162b2 Vaccine against Omicron variant in South Africa. N Engl J Med. 2022;386(5):494\u20136.","journal-title":"N Engl J Med"},{"issue":"7","key":"2600_CR21","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/S1473-3099(21)00070-0","volume":"21","author":"R Ella","year":"2021","unstructured":"Ella R, Reddy S, Jogdand H, Sarangi V, Ganneru B, Prasad S, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Dis. 2021;21(7):950\u201361.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"2600_CR22","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S1473-3099(20)30942-7","volume":"21","author":"R Ella","year":"2021","unstructured":"Ella R, Vadrevu KM, Jogdand H, Prasad S, Reddy S, Sarangi V, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis. 2021;21(5):637\u201346.","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"2600_CR23","doi-asserted-by":"publisher","first-page":"e1003769","DOI":"10.1371\/journal.pmed.1003769","volume":"18","author":"N Formica","year":"2021","unstructured":"Formica N, Mallory R, Albert G, Robinson M, Plested JS, Cho I, et al. nCo VSG: Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: a phase 2 randomized placebo-controlled trial. Plos Med. 2021;18(10):e1003769.","journal-title":"Plos Med"},{"issue":"9","key":"2600_CR24","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/S1473-3099(21)00147-X","volume":"21","author":"PA Goepfert","year":"2021","unstructured":"Goepfert PA, Fu B, Chabanon AL, Bonaparte MI, Davis MG, Essink BJ, et al. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study. Lancet Infect Dis. 2021;21(9):1257\u201370.","journal-title":"Lancet Infect Dis"},{"key":"2600_CR25","doi-asserted-by":"publisher","first-page":"101010","DOI":"10.1016\/j.eclinm.2021.101010","volume":"38","author":"W Guo","year":"2021","unstructured":"Guo W, Duan K, Zhang Y, Yuan Z, Zhang YB, Wang Z, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1\/2 trial. EClinicalMedicine. 2021;38:101010.","journal-title":"EClinicalMedicine"},{"issue":"12","key":"2600_CR26","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/S1473-3099(21)00319-4","volume":"21","author":"B Han","year":"2021","unstructured":"Han B, Song Y, Li C, Yang W, Ma Q, Jiang Z, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1\/2 clinical trial. Lancet Infect Dis. 2021;21(12):1645\u201353.","journal-title":"Lancet Infect Dis"},{"issue":"13","key":"2600_CR27","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","volume":"385","author":"PT Heath","year":"2021","unstructured":"Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med. 2021;385(13):1172\u201383.","journal-title":"N Engl J Med"},{"key":"2600_CR28","doi-asserted-by":"publisher","first-page":"100989","DOI":"10.1016\/j.eclinm.2021.100989","volume":"38","author":"SM Hsieh","year":"2021","unstructured":"Hsieh SM, Liu WD, Huang YS, Lin YJ, Hsieh EF, Lian WC, et al. Safety and immunogenicity of a recombinant stabilized prefusion SARS-CoV-2 spike protein vaccine (MVC-COV1901) adjuvanted with CpG 1018 and aluminum hydroxide in healthy adults: a phase 1, dose-escalation study. EClinicalMedicine. 2021;38:100989.","journal-title":"EClinicalMedicine"},{"issue":"20","key":"2600_CR29","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","volume":"383","author":"LA Jackson","year":"2020","unstructured":"Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med. 2020;383(20):1920\u201331.","journal-title":"N Engl J Med"},{"issue":"24","key":"2600_CR30","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","volume":"383","author":"C Keech","year":"2020","unstructured":"Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle Vaccine. N Engl J Med. 2020;383(24):2320\u201332.","journal-title":"N Engl J Med"},{"issue":"17-18","key":"2600_CR31","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00508-021-01922-y","volume":"133","author":"PG Kremsner","year":"2021","unstructured":"Kremsner PG, Mann P, Kroidl A, Leroux-Roels I, Schindler C, Gabor JJ, et al. Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : a phase 1 randomized clinical trial. Wien Klin Wochenschr. 2021;133(17-18):931\u201341.","journal-title":"Wien Klin Wochenschr"},{"issue":"6","key":"2600_CR32","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/s41591-021-01330-9","volume":"27","author":"J Li","year":"2021","unstructured":"Li J, Hui A, Zhang X, Yang Y, Tang R, Ye H, et al. Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nat Med. 2021;27(6):1062\u201370.","journal-title":"Nat Med"},{"issue":"1","key":"2600_CR33","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1080\/22221751.2021.1969291","volume":"10","author":"XN Li","year":"2021","unstructured":"Li XN, Huang Y, Wang W, Jing QL, Zhang CH, Qin PZ, et al. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study. Emerg Microbes Infect. 2021;10(1):1751\u20139.","journal-title":"Emerg Microbes Infect"},{"issue":"7","key":"2600_CR34","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2108891","volume":"385","author":"J Lopez Bernal","year":"2021","unstructured":"Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021;385(7):585\u201394.","journal-title":"N Engl J Med"},{"issue":"20","key":"2600_CR35","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1056\/NEJMoa2102214","volume":"384","author":"SA Madhi","year":"2021","unstructured":"Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. N Engl J Med. 2021;384(20):1885\u201398.","journal-title":"N Engl J Med"},{"issue":"1","key":"2600_CR36","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41392-021-00692-3","volume":"6","author":"FY Meng","year":"2021","unstructured":"Meng FY, Gao F, Jia SY, Wu XH, Li JX, Guo XL, et al. Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials. Signal Transduct Target Ther. 2021;6(1):271.","journal-title":"Signal Transduct Target Ther"},{"key":"2600_CR37","doi-asserted-by":"publisher","first-page":"101020","DOI":"10.1016\/j.eclinm.2021.101020","volume":"38","author":"T Momin","year":"2021","unstructured":"Momin T, Kansagra K, Patel H, Sharma S, Sharma B, Patel J, et al. Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I\/II clinical study by intradermal route in healthy subjects in India. EClinicalMedicine. 2021;38:101020.","journal-title":"EClinicalMedicine"},{"issue":"7830","key":"2600_CR38","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","volume":"586","author":"MJ Mulligan","year":"2020","unstructured":"Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586(7830):589\u201393.","journal-title":"Nature"},{"issue":"3","key":"2600_CR39","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41564-021-01053-0","volume":"7","author":"S Nasreen","year":"2022","unstructured":"Nasreen S, Chung H, He S, Brown KA, Gubbay JB, Buchan SA, et al. Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario. Nat Microbiol. 2022;7(3):379\u201385.","journal-title":"Nat Microbiol"},{"issue":"11","key":"2600_CR40","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1097\/CM9.0000000000001573","volume":"134","author":"HX Pan","year":"2021","unstructured":"Pan HX, Liu JK, Huang BY, Li GF, Chang XY, Liu YF, et al. Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials. Chin Med J (Engl). 2021;134(11):1289\u201398.","journal-title":"Chin Med J (Engl)"},{"issue":"10275","key":"2600_CR41","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S0140-6736(21)00241-5","volume":"397","author":"P Richmond","year":"2021","unstructured":"Richmond P, Hatchuel L, Dong M, Ma B, Hu B, Smolenov I, et al. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10275):682\u201394.","journal-title":"Lancet"},{"issue":"19","key":"2600_CR42","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, et al. Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med. 2021;384(19):1824\u201335.","journal-title":"N Engl J Med"},{"issue":"7830","key":"2600_CR43","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","volume":"586","author":"U Sahin","year":"2020","unstructured":"Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020;586(7830):594\u20139.","journal-title":"Nature"},{"issue":"10293","key":"2600_CR44","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(21)01358-1","volume":"397","author":"A Sheikh","year":"2021","unstructured":"Sheikh A, McMenamin J, Taylor B, Robertson C, Public Health S. the EIIC: SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021;397(10293):2461\u20132.","journal-title":"Lancet"},{"issue":"16","key":"2600_CR45","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1097\/CM9.0000000000001702","volume":"134","author":"YJ Shu","year":"2021","unstructured":"Shu YJ, He JF, Pei RJ, He P, Huang ZH, Chen SM, et al. Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial. Chin Med J (Engl). 2021;134(16):1967\u201376.","journal-title":"Chin Med J (Engl)"},{"key":"2600_CR46","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"issue":"12","key":"2600_CR47","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1038\/s41591-021-01583-4","volume":"27","author":"P Tang","year":"2021","unstructured":"Tang P, Hasan MR, Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nat Med. 2021;27(12):2136\u201343.","journal-title":"Nat Med"},{"key":"2600_CR48","doi-asserted-by":"publisher","first-page":"100689","DOI":"10.1016\/j.eclinm.2020.100689","volume":"31","author":"P Tebas","year":"2021","unstructured":"Tebas P, Yang S, Boyer JD, Reuschel EL, Patel A, Christensen-Quick A, et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of an open-label, phase 1 clinical trial. EClinicalMedicine. 2021;31:100689.","journal-title":"EClinicalMedicine"},{"issue":"5","key":"2600_CR49","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s41591-022-01753-y","volume":"28","author":"HF Tseng","year":"2022","unstructured":"Tseng HF, Ackerson BK, Luo Y, Sy LS, Talarico CA, Tian Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med. 2022;28(5):1063\u201371.","journal-title":"Nat Med"},{"issue":"25","key":"2600_CR50","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","volume":"383","author":"EE Walsh","year":"2020","unstructured":"Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439\u201350.","journal-title":"N Engl J Med"},{"issue":"1","key":"2600_CR51","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa2116298","volume":"386","author":"EB Walter","year":"2022","unstructured":"Walter EB, Talaat KR, Sabharwal C, Gurtman A, Lockhart S, Paulsen GC, et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of Age. N Engl J Med. 2022;386(1):35\u201346.","journal-title":"N Engl J Med"},{"issue":"6","key":"2600_CR52","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s41591-021-01370-1","volume":"27","author":"BJ Ward","year":"2021","unstructured":"Ward BJ, Gobeil P, Seguin A, Atkins J, Boulay I, Charbonneau PY, et al. Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19. Nat Med. 2021;27(6):1071\u20138.","journal-title":"Nat Med"},{"issue":"12","key":"2600_CR53","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/S1473-3099(21)00396-0","volume":"21","author":"S Wu","year":"2021","unstructured":"Wu S, Huang J, Zhang Z, Wu J, Zhang J, Hu H, et al. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Lancet Infect Dis. 2021;21(12):1654\u201364.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"2600_CR54","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S1473-3099(20)30987-7","volume":"21","author":"Z Wu","year":"2021","unstructured":"Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial. Lancet Infect Dis. 2021;21(6):803\u201312.","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"2600_CR55","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1001\/jama.2020.15543","volume":"324","author":"S Xia","year":"2020","unstructured":"Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020;324(10):951\u201360.","journal-title":"JAMA"},{"issue":"1","key":"2600_CR56","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","volume":"21","author":"S Xia","year":"2021","unstructured":"Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial. Lancet Infect Dis. 2021;21(1):39\u201351.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"2600_CR57","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S1473-3099(21)00462-X","volume":"22","author":"S Xia","year":"2022","unstructured":"Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1\/2 trial. Lancet Infect Dis. 2022;22(2):196\u2013208.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"2600_CR58","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S1473-3099(21)00127-4","volume":"21","author":"S Yang","year":"2021","unstructured":"Yang S, Li Y, Dai L, Wang J, He P, Li C, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 2021;21(8):1107\u201319.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"2600_CR59","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1080\/22221751.2021.1951126","volume":"10","author":"J Zhang","year":"2021","unstructured":"Zhang J, Hu Z, He J, Liao Y, Li Y, Pei R, et al. Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial. Emerg Microbes Infect. 2021;10(1):1589\u201397.","journal-title":"Emerg Microbes Infect"},{"issue":"2","key":"2600_CR60","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","volume":"21","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial. Lancet Infect Dis. 2021;21(2):181\u201392.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"2600_CR61","doi-asserted-by":"publisher","first-page":"e783","DOI":"10.1093\/cid\/ciab845","volume":"75","author":"F Zhu","year":"2022","unstructured":"Zhu F, Jin P, Zhu T, Wang W, Ye H, Pan H, et al. Safety and immunogenicity of a recombinant adenovirus type-5-vectored Coronavirus Disease 2019 (COVID-19) vaccine with a homologous prime-boost regimen in healthy participants aged >\/=6 years: a randomized, double-blind, placebo-controlled, phase 2b trial. Clin Infect Dis. 2022;75(1):e783\u201391.","journal-title":"Clin Infect Dis"},{"issue":"10249","key":"2600_CR62","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","volume":"396","author":"FC Zhu","year":"2020","unstructured":"Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396(10249):479\u201388.","journal-title":"Lancet"},{"issue":"10240","key":"2600_CR63","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","volume":"395","author":"FC Zhu","year":"2020","unstructured":"Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395(10240):1845\u201354.","journal-title":"Lancet"},{"key":"2600_CR64","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135.","journal-title":"BMC Med Res Methodol"},{"issue":"20","key":"2600_CR65","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1056\/NEJMoa2103055","volume":"384","author":"V Shinde","year":"2021","unstructured":"Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, et al. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021;384(20):1899\u2013909.","journal-title":"N Engl J Med"},{"issue":"2","key":"2600_CR66","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s43588-022-00198-0","volume":"2","author":"P Padmanabhan","year":"2022","unstructured":"Padmanabhan P, Desikan R, Dixit NM. Modeling how antibody responses may determine the efficacy of COVID-19 vaccines. Nat Comput Sci. 2022;2(2):123\u201331.","journal-title":"Nat Comput Sci"},{"issue":"5","key":"2600_CR67","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41591-022-01736-z","volume":"28","author":"Z Du","year":"2022","unstructured":"Du Z, Wang L, Pandey A, Lim WW, Chinazzi M, Piontti APY, et al. Modeling comparative cost-effectiveness of SARS-CoV-2 vaccine dose fractionation in India. Nat Med. 2022;28(5):934\u20138.","journal-title":"Nat Med"},{"key":"2600_CR68","doi-asserted-by":"publisher","unstructured":"Nishiura H, Ito K, Anzai A, Kobayashi T, Piantham C, Rodr\u00edguez-Morales AJ. Relative Reproduction Number of SARS-CoV-2 Omicron (B.1.1.529) Compared with Delta Variant in South Africa. J Clin Med. 2021;11(1):30. https:\/\/doi.org\/10.3390\/jcm11010030.","DOI":"10.3390\/jcm11010030"},{"issue":"4","key":"2600_CR69","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","volume":"184","author":"A Sette","year":"2021","unstructured":"Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184(4):861\u201380.","journal-title":"Cell"},{"issue":"4","key":"2600_CR70","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","volume":"183","author":"C Rydyznski Moderbacher","year":"2020","unstructured":"Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183(4):996\u20131012 e1019.","journal-title":"Cell"},{"issue":"1","key":"2600_CR71","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/s41467-022-28527-x","volume":"13","author":"H Ward","year":"2022","unstructured":"Ward H, Whitaker M, Flower B, Tang SN, Atchison C, Darzi A, et al. Population antibody responses following COVID-19 vaccination in 212,102 individuals. Nat Commun. 2022;13(1):907.","journal-title":"Nat Commun"},{"issue":"11","key":"2600_CR72","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMc2119432","volume":"386","author":"LJ Abu-Raddad","year":"2022","unstructured":"Abu-Raddad LJ, Chemaitelly H, Bertollini R. National Study Group for C-V: waning mRNA-1273 vaccine effectiveness against SARS-CoV-2 infection in Qatar. N Engl J Med. 2022;386(11):1091\u20133.","journal-title":"N Engl J Med"},{"key":"2600_CR73","doi-asserted-by":"publisher","first-page":"103904","DOI":"10.1016\/j.ebiom.2022.103904","volume":"77","author":"Q Peng","year":"2022","unstructured":"Peng Q, Zhou R, Wang Y, Zhao M, Liu N, Li S, et al. Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong. EBioMedicine. 2022;77:103904.","journal-title":"EBioMedicine"},{"key":"2600_CR74","doi-asserted-by":"publisher","DOI":"10.5281\/zenodo.7152048","volume-title":"byyangyby\/fractional_dose_review: Fractional dose review","author":"B Yang","year":"2022","unstructured":"Yang B, Huang X, Gao H, Leung NH, Tsang TK, Cowling BJ. byyangyby\/fractional_dose_review: Fractional dose review: Zenodo; 2022. https:\/\/doi.org\/10.5281\/zenodo.7152048."}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02600-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-022-02600-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02600-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T22:03:54Z","timestamp":1667081034000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-022-02600-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,25]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2600"],"URL":"https:\/\/doi.org\/10.1186\/s12916-022-02600-0","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,25]]},"assertion":[{"value":"6 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"B.J.C. consults for AstraZeneca, GSK, Moderna, Roche, Sanofi Pasteur, and Pfizer. The remaining authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"409"}}